Finerenone in Heart Failure with Preserved Ejection Fraction

To the Editor: Solomon et al. (Oct. 24 issue) 1 found that among patients with heart failure and mildly reduced or preserved ejection fraction, finerenone resulted in a lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo, with a rate ratio of 0.84 (95% confidence interval [CI], 0.74 to 0.95). Finerenone is the first mineralocorticoid receptor antagonist that has shown a benefit in this patient population after the negative results with spironolactone in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. 2 The authors propose that the . . .